Leaflet RILUZOL PMCS 50mg film-coated tablets


Indicated for: amyotrophic lateral sclerosis

Route of administration: oral

Substance: riluzole (glutamate modulator)

ATC: N07XX02 (Nervous system | Other nervous system drugs)

Riluzole is a medication used for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. It works by reducing the release of glutamate, a neurotransmitter that can be toxic to motor neurons in excess.

The medication is taken orally, as directed by a doctor, usually twice daily. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor liver function.

Patients should be aware of potential side effects, such as nausea, fatigue, or elevated liver enzyme levels. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, fatigue, and elevated liver enzyme levels. In rare cases, severe reactions such as hepatotoxicity or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about RILUZOL PMCS 50mg

  • Substance: riluzole
  • Date of last drug list: 01-07-2013
  • Commercial code: W58642001
  • Concentration: 50mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 10
  • Product type: generic
  • Prescription restrictions: X

Marketing authorisation

  • Manufacturer: PRO. MED. CS PRAHA A.S. - REPUBLICA CEHA
  • Holder: PRO. MED. CS PRAHA A.S. - REPUBLICA CEHA
  • Number: 9930/2017/01
  • Shelf life: 2 years